Poor Muscle Status, Dietary Protein Intake, Exercise Levels, Quality of Life and Physical Function in Women with Metastatic Breast Cancer at Chemotherapy Commencement and during Follow-Up
Current Oncology · 2023
DOI: 10.3390/curroncol30010054 ↗Kurz gefasst
Fachartikel in der Zeitschrift Current Oncology, 2023. Verfasst von Jessica Parkinson und 8 weiteren Autor:innen. Beteiligte Einrichtung: Bond University Nutrition and Dietetics Research Group, Faculty of Health Sciences and Medicine, Bond University, Gold Coast, QLD 4226, Australia. Hauptthemen laut MEDLINE: Breast Neoplasms, Sarcopenia. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Onkologische Pflege
Abstract (Originalsprache)
This study aimed to investigate nutritional status, body composition, dietary protein intake, handgrip strength, 6 min or 4 m walk tests, self-reported physical activity, physical function, and quality of life (QoL-EORTC-QLQc30) at commencement of chemotherapy; to detect changes over time (from commencement of chemotherapy, and after 3, 6, 12, 26 and 52 weeks) in women with metastatic breast cancer (MBC); and to investigate the relationship between nutritional variables. ‘Sarcopenia’ was defined as low muscle mass and strength, ‘myosteatosis’ as muscle fat-infiltration (CT scan). Continuous variables were analysed using paired t-tests between baseline and follow-ups. Fifteen women (54y, 95% CI [46.3;61.2]) were recruited. At baseline, malnutrition was present in 3 (20%) participants, sarcopenia in 3 (20%) and myosteatosis in 7 (54%). Thirteen (87%) participants had low protein intake; low handgrip strength was observed in 0, and low walk test distance and physical activity in four (27%) participants. Physical function and QoL were low in 10 (67%) and 9 (60%), respectively. QoL between baseline and 52 weeks decreased by 11.7 (95% CI [2.4;20.9], p = 0.025). Other variables did not significantly change over time. In this small study sample, myosteatosis, low dietary protein intake, low exercise levels and impaired quality of life and physical function are common.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Bond University Nutrition and Dietetics Research Group, Faculty of Health Sciences and Medicine, Bond University, Gold Coast, QLD 4226, Australia.
- Mater Health, Brisbane, QLD 4101, Australia.
- Mater Research Institute, University of Queensland, Brisbane, QLD 4072, Australia.
- Department of Nutrition, Dietetics and Lifestyle, HAN University of Applied Sciences, 6525 EN Nijmegen, The Netherlands.
- Division of Human Nutrition and Health, Wageningen University and Research, 6708 PD Wageningen, The Netherlands.
ORCID-Profile: Jessica Parkinson, Megan Crichton, Barbara S van der Meij
Zitieren
APA
Parkinson, J., Bandera, A., Crichton, M., Shannon, C., Woodward, N., Hodgkinson, A., Millar, L., Teleni, L., & van der Meij, B. S. (2023). Poor Muscle Status, Dietary Protein Intake, Exercise Levels, Quality of Life and Physical Function in Women with Metastatic Breast Cancer at Chemotherapy Commencement and during Follow-Up. Current Oncology. https://doi.org/10.3390/curroncol30010054
Vancouver
Parkinson J, Bandera A, Crichton M, Shannon C, Woodward N, Hodgkinson A, et al. Poor Muscle Status, Dietary Protein Intake, Exercise Levels, Quality of Life and Physical Function in Women with Metastatic Breast Cancer at Chemotherapy Commencement and during Follow-Up. Current Oncology. 2023. doi:10.3390/curroncol30010054
BibTeX
@article{Parkinson2023,
author = {Parkinson, Jessica and Bandera, Amelia and Crichton, Megan and Shannon, Catherine and Woodward, Natasha and Hodgkinson, Adam and Millar, Luke and Teleni, Laisa and van der Meij, Barbara S},
title = {Poor Muscle Status, Dietary Protein Intake, Exercise Levels, Quality of Life and Physical Function in Women with Metastatic Breast Cancer at Chemotherapy Commencement and during Follow-Up},
journal = {Current Oncology},
year = {2023},
doi = {10.3390/curroncol30010054}
}
EUVIMED